• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Novo A/S

edit

Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation. Novo A/S is the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S’ objective is to manage the Foundation’s financial assets through investments in the life science area and in a broad portfolio of financial assets.

Recent Milestones

edit

• 
  Novo A/S invested in Symphogen. (5/3/13)
  Posted 5/7/13 at 2:52am via finsmes.com
• 
  Novo A/S invested in PTC Therapeutics. (3/7/13)
  Posted 3/7/13 at 7:00pm via finsmes.com
• 
  Novo A/S invested in Karus Therapeutics . (9/6/12)
  Posted 9/6/12 at 11:58pm via dowjones.com
• 
  Novo A/S invested in PTC Therapeutics. (7/23/12)
  Posted 7/23/12 at 6:11pm via finsmes.com
• 
  Novo A/S invested in Santaris Pharma. (6/21/12)
  Posted 6/21/12 at 7:09pm via dowjones.com
• 
  Novo A/S invested in Inogen. (4/12/12)
  Posted 4/12/12 at 6:49pm via inogenone.com
• 
  Novo A/S invested in AlloCure. (4/2/12)
  Posted 4/2/12 at 5:19pm via masshightech.com
• 
  Novo A/S invested in Tarsa Therapeutics. (3/16/12)
  Posted 3/16/12 at 5:50am via prnewswire.com
• 
  Novo A/S invested in Altheos. (2/9/12)
  Posted 2/9/12 at 6:40pm via fiercebiotech.com
• 
  Novo A/S invested in Orphazyme. (9/7/11)
  Posted 9/7/11 at 6:46pm via fiercebiotech.com
• 
  Novo A/S invested in KalVista Pharmaceuticals. (8/23/11)
  Posted 8/23/11 at 5:15am via prnewswire.com
• 
  Novo A/S invested in Vantia Therapeutics. (7/6/11)
  Posted 7/6/11 at 6:56pm via vantiatherapeutics.com
• 
  Novo A/S invested in HTG Molecular Diagnostics. (2/24/11)
  Posted 6/13/11 at 6:49pm via finsmes.com
• 
  Novo A/S invested in High Throughput Genomics. (2/23/11)
  Posted 2/24/11 at 10:27pm via htgenomics.com
• 
  Novo A/S invested in Symphogen. (2/14/11)
  Posted 2/14/11 at 4:01am via onbiovc.com
• 
  Novo A/S invested in Orphazyme. (2/14/11)
  Posted 3/27/11 at 5:25pm via orphazyme.com

Investments

Videos

Sources

1. Symphogen Closes Additional €41M Financing (finsmes.com) [edit]
2. PTC Therapeutics Completes $60M Financing (finsmes.com) [edit]
3. Karus Thera Picks Up $7.6M to Develop Two Preclinical Compounds (pevc.dowjones.com) [edit]
4. PTC Therapeutics Completes $30M Financing (finsmes.com) [edit]
5. Denmark's Santaris Grabs $12M From Insiders for Clinical Trials (pevc.dowjones.com) [edit]
6. Inogen Secures $20 Million in Financing Led by Novo A/S (inogenone.com) [edit]
7. AlloCure raises $25M round for kidney disease trial (masshightech.com) [edit]
8. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin (prnewswire.com) [edit]
9. Altheos grabs $12.5M more, launches glaucoma trial (fiercebiotech.com) [edit]
10. Orphazyme lands $20M A round to back new drugs for rare genetic disorder (fiercebiotech.com) [edit]
11. KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema (prnewswire.com) [edit]
12. Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds (vantiatherapeutics.com) [edit]
13. HTG Molecular Diagnostics Receives $500k from SR One in Series D Financing (finsmes.com) [edit]
14. HTG Completes First Tranche of $15.7 Million Series D Financing (htgenomics.com) [edit]
15. Symphogen, AS: Series F $135.4M (onbiovc.com) [edit]
16. Orphazyme raises 22 mDKK in a seed round extension; Sunstone Capital joins as new investor (orphazyme.com) [edit]
17. Symphogen Closes €100M Round of Financing (finsmes.com) [edit]
18. Cell Biosciences Nabs $20M (xconomy.com) [edit]
19. Synosia Therapeutics Raises $30M in Series C Financing (synosia.com) [edit]
20. Tobira Therapeutics Inc. Raises $31 Million in Series B Financing (tobiratherapeutics.com) [edit]
21. Reata Pharmaceuticals Completes $78 Million Equity Financing for Second Pivotal Trial of Bardoxolone Methy (reatapharma.com) [edit]
22. Logical Therapeutics closes $16.9M round for NSAID program (fiercebiotech.com) [edit]
23. EDGAR [edit]
24. Glaucoma drug focus inspires $20M A round for Altheos (fiercebiotech.com) [edit]
25. Archimedes Pharma, Ltd.: Series C $99M (onbiovc.com) [edit]
26. PTC Therapeutics Raises 50M in Equity Financing (finsmes.com) [edit]
27. Ophthotech nabs $30M round to fund AMD trial (fiercebiotech.com) [edit]
28. Cell Biosciences Raises $4M and Acquires Protein Forest (finsmes.com) [edit]
29. Lux Biosciences scores $50M Series B for eye cure (venturebeat.com) [edit]
30. Cell Biosciences Raises $10 Million (pehub.com) [edit]
31. Antibody Engineering Company F-Star Raises EUR 3.0 million in a Second Closing of its Series A Financing Round from Novo A/S (f-star.com) [edit]
32. AnaptysBio raises over $33 million in Series B financing (anaptysbio.com) [edit]
33. Neurological co. Synosis raises $32.5M (deals.venturebeat.com) [edit]
34. MediQuest Therapeutics Raises $16.0 Million In Series A Financing (mqti.com) [edit]
35. New owners invest in Celltrix technology (celltrix.se) [edit]
36. Symphogen gets $25M for clinical trials for bleeding treatment (bulletin.sciencebusiness.net) [edit]
37. LIGHT SCIENCES ONCOLOGY COMPLETES SECOND CLOSING IN $67 MILLION FINANCING FOR LATE STAGE DEVELOPMENT OF LITXâ„¢ AND ANNOUNCES ADDITIONAL DIRECTORS (lsoncology.com) [edit]
38. PTC THERAPEUTICS RAISES $26.6 MILLION IN PRIVATE PLACEMENT FINANCING (ptct.client.shareholder.com) [edit]